Literature DB >> 35182165

Concerns about study design and suggestion of additional analysis of therapeutic drug monitoring-guided piperacillin/tazobactam therapy for patients with sepsis.

Shodai Yoshihiro1, Shunsuke Taito2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35182165     DOI： 10.1007/s00134-022-06648-7

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN： 0342-4642            Impact factor:   41.787


× No keyword cloud information.
  4 in total

1.  Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model.

Authors:  J W Mouton; J G den Hollander
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

2.  Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America.

Authors:  Joshua P Metlay; Grant W Waterer; Ann C Long; Antonio Anzueto; Jan Brozek; Kristina Crothers; Laura A Cooley; Nathan C Dean; Michael J Fine; Scott A Flanders; Marie R Griffin; Mark L Metersky; Daniel M Musher; Marcos I Restrepo; Cynthia G Whitney
Journal:  Am J Respir Crit Care Med       Date:  2019-10-01       Impact factor: 21.405

3.  DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients?

Authors:  Jason A Roberts; Sanjoy K Paul; Murat Akova; Matteo Bassetti; Jan J De Waele; George Dimopoulos; Kirsi-Maija Kaukonen; Despoina Koulenti; Claude Martin; Philippe Montravers; Jordi Rello; Andrew Rhodes; Therese Starr; Steven C Wallis; Jeffrey Lipman
Journal:  Clin Infect Dis       Date:  2014-01-14       Impact factor: 9.079

4.  Another trial for the TARGET trial. Author's reply.

Authors:  Stefan Hagel; Mathias W Pletz; Thomas Lehmann
Journal:  Intensive Care Med       Date:  2022-03-23       Impact factor: 41.787
  4 in total
  1 in total

1.  Concerns about study design and suggestion of additional analysis of therapeutic drug monitoring-guided piperacillin/tazobactam therapy for patients with sepsis. Author's reply.

Authors:  Stefan Hagel; Mathias W Pletz; Thomas Lehmann
Journal:  Intensive Care Med       Date:  2022-03-15       Impact factor: 41.787
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.